

PRV

PATENT- OCH REGISTRERINGSVERKET

Patentavdelningen

REC'D 05 JAN 2005

WIPO

PCT

**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0303451-9
Patent application number

(86) Ingivningsdatum 2003-12-18
Date of filing

Stockholm, 2004-10-20

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

**PATENT- OCH
REGISTRERINGSVERKET**
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

NEW COMPOUNDS

Field of the invention

5 The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt. Further, the present invention also relates to use of said compounds for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them and processes for obtaining them.

10

Background of the invention and prior art

In the formulation of drug compositions, it is important for the drug substance to be in a form in which it can be conveniently handled and processed. This is of importance, not
15 only from the point of view of obtaining a commercially viable manufacturing process, but also from the point of view of subsequent manufacture of pharmaceutical formulations comprising the active compound.

Further, in the manufacture of oral drug compositions, it is important that a reliable,
20 reproducible and constant plasma concentration profile of drug is provided following administration to a patient.

Chemical stability, solid state stability, and "shelf life" of the active ingredients are also very important factors. The drug substance, and compositions containing it, should be
25 capable of being effectively stored over appreciable periods of time, without exhibiting a significant change in the physico-chemical characteristics of the active component, e.g. its chemical composition, density, hygroscopicity and solubility.

Amorphous materials may present problems in this regard. For example, such materials are
30 typically more difficult to handle and to formulate, provide for unreliable solubility, and are often found to be more unstable.

Thus, in the manufacture of commercially viable and pharmaceutically acceptable drug compositions, it is important, wherever possible, to provide the drug in a substantially crystalline and stable form(s).

5 International patent applications WO 99/55705 and WO 99/55706 disclose a number of compounds, referred to as imidazo pyridine derivatives, which are potassium-competitive inhibitors of acid secretion.

10 *Brief description of the drawings*

Figure 1 is an X-ray powder diffractogram of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A.

15 Figure 2 is an X-ray powder diffractogram of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.

Description of the invention

20 It has surprisingly been found that 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt can exist in more than one crystal form. The crystal forms are hereinafter referred to as 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and form B, and also to as the crystal forms of the invention. The notation A and B relates to the order in time in which the forms were invented, not to their relative thermodynamic stability.

25
30 It is thus an object of the present invention to provide crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt with advantageous properties.

It is an aspect of the present invention to provide 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A.

- 5 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A, according to the present invention, is characterized in providing an X-ray powder diffraction pattern, as in figure 1, exhibiting substantially the following d-values:

Form A		
d-value (Å)	d-value (Å)	d-value (Å)
11.4	5.0	3.96
9.3	4.72	3.92
8.0	4.66	3.86
7.8	4.62	3.68
7.3	4.49	3.63
6.8	4.43	3.56
6.1	4.35	3.42
5.8	4.29	3.18
5.7	4.10	

10

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A according to the present invention is further characterized by a monoclinic unit cell with parameters:

15 $a = 8.6 \text{ Å}, b = 18.7 \text{ Å}, c = 15.8 \text{ Å}, \alpha = 90^\circ, \beta = 113^\circ, \gamma = 90^\circ.$

It is a further aspect of the present invention to provide 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B, according to the present invention, is characterized in providing an X-ray powder diffraction pattern, as in figure 2, exhibiting substantially the following d-values:

Form B		
d-value (Å)	d-value (Å)	d-value (Å)
19.5	6.8	4.72
11.8	6.5	4.52
11.1	6.4	4.35
9.8	5.9	3.89
8.3	5.5	3.68
7.8	4.96	3.26

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B according to the present invention is further

characterized by a triclinic unit cell with parameters: $a = 8.4 \text{ Å}$, $b = 14.2 \text{ Å}$, $c = 19.9 \text{ Å}$, $\alpha = 93^\circ$, $\beta = 100^\circ$, $\gamma = 96^\circ$.

The compound of the invention, i.e. 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A, prepared according to the present invention is analyzed, characterized and differentiated from 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B by X-ray powder diffraction, a technique which is known per se. Another suitable technique to analyze, characterize and differentiate 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A from 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B is by Raman spectroscopy.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B are crystalline forms exhibiting advantageous properties, such as convenient handling as well as chemical and physical stability.

It is possible to crystallize 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and form B, i.e. the crystal forms of the present invention in one single solvent, in a mixture of solvents, or in an aqueous or methanolic mixture thereof. However, it is preferred that the crystallization is from a lower alcohol, or from an aqueous or methanolic mixture thereof.

The term "lower alcohol" includes herein a linear or branched C₂-C₃-alcohol, such as ethanol and *iso*-propanol.

Crystallization of compounds of the present invention from an appropriate solvent system, containing at least one solvent, may be achieved by attaining supersaturation in a solvent system by solvent evaporation, by temperature decrease, and/or via the addition of anti-solvent (i.e. a solvent in which the compounds of the invention are poorly soluble).

Crystallization may be initiated and/or effected with or without seeding with crystals of the appropriate crystalline compound of the invention.

Crystallization of compounds of the present invention can be achieved by in situ formation of the salt starting from pure 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide as well as starting from 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt of any form, or mixtures of any form.

Whether an anhydrate or solvate crystallizes is related to the kinetics and equilibrium conditions of the respective forms at the specific conditions. Thus, as may be appreciated

by the skilled person, the crystalline form that is obtained depends upon both the kinetics and the thermodynamics of the crystallization process. Under certain conditions (solvent system, temperature, pressure and concentration of compound of the invention), one crystalline form may be more stable than another (or indeed any other). However, 5 crystalline forms that have a relatively low thermodynamic stability may be kinetically favored. Thus, in addition, kinetic factors, such as time, impurity profile, agitation, the presence or absence of seeds, etc. may also influence which form that crystallizes.

One object of the present invention is to provide processes for the preparation of 2,3- 10 dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and form B.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6- 15 carboxamide mesylate salt form A is obtainable upon crystallization from a lower alcohol or from a mixture thereof, or from an aqueous or methanolic mixture thereof. The crystallization is performed at a higher temperature, i.e. at a temperature of 40 °C or above, preferably at a temperature of 50 °C or above.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6- 20 carboxamide mesylate salt form B is obtainable upon crystallization from a lower alcohol, or from a mixture thereof, or from an aqueous or methanolic mixture thereof. The crystallization is performed at a lower temperature, i.e. at a temperature lower than 40 °C, preferably at room temperature, i.e. at 20 °C, most preferably at 10 °C or below.

25 In order to ensure that a particular crystalline form is prepared in the substantial absence of other crystalline forms, crystallization is preferably carried out by seeding with seed crystals of the desired crystalline form. This applies particularly to each of the specific crystalline forms which are described in the Examples.

30 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and form B obtainable according to the present invention are substantially free from other crystalline and non-crystalline forms of 2,3-

dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt. The term "substantially free from other crystalline and non-crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt" shall be understood to mean that the
5 desired crystal form of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt contains less than 10 %, preferably less than 5 %, more preferably less than 3 %, and even more preferably less than 1 % of any other forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt.

10 Another aspect of the invention is mixtures of different crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt.

15 One aspect of the invention is mixtures of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B wherein the mixture contains any amount of form B, such as a detectable amount, 1 %, 2 %, 3 %, 4 %, 5 %, 6 %, 7 %, 8 %, 9 %, 10 %, 11 %, 12
20 %, 13 %, 14 %, 15 %, 16 %, 17 %, 18 %, 19 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 81 %, 82 %, 83 %, 84 %, 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % (by weight) of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B. Such mixtures can also be obtained by simply mixing the two forms, form A
25 and form B.

In a further aspect, the invention relates to the compound of the invention for use in therapy, in particular for use against gastrointestinal inflammatory diseases. The invention
30 also provides the use of the compound of the invention in the manufacture of a medicament for the inhibition of gastric acid secretion, or for the treatment of gastrointestinal inflammatory diseases.

The compounds according to the invention may thus be used for prevention and treatment of gastrointestinal inflammatory diseases, and gastric acid-related diseases in mammals including man, such as gastritis, gastric ulcer, duodenal ulcer, peptic ulcer diseases, reflux esophagitis and Zollinger-Ellison syndrome. Furthermore, the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable, e.g. in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding.

The compounds may also be used for effective control and treatment of heartburn and other Gastroesophageal Reflux Disease (GERD) symptoms, i.e. healing of erosive esophagitis, maintenance of erosive esophagitis, symptomatic GERD, long term management of symptomatic GERD; heartburn regurgitation; short and long-term management of acid reflux disease; and nausea. They may also be used in patients in intensive care situations, and pre- and postoperatively to prevent acid aspiration and stress ulceration.

The typical daily dose of the compounds of the invention varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 1 to 1000 mg per day of active substance.

The compounds of the invention may be further processed before formulation into a suitable pharmaceutical formulation. For example, the crystalline form may be milled or ground into smaller particles.

According to a further aspect of the invention, there is provided a pharmaceutical formulation including one of the compounds of the invention, or a mixture of form A and form B of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt in admixture with at least one pharmaceutically acceptable adjuvant, diluent or carrier.

For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other modes of administration. The

pharmaceutical formulation contains a compound of the invention, or a mixture of the compounds, in combination with one or more pharmaceutically acceptable ingredients. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compounds is between 0.1 % and 95 % by weight of the preparation, preferably between 0.1 % and 20 % by weight in preparations for parenteral use and preferably between 0.1 % and 50 % by weight in preparations for oral administration.

In the preparation of pharmaceutical formulations containing the crystal forms of the present invention, or a mixture thereof, in the form of dosage units for oral administration the compound selected may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or pressed into tablets.

Soft gelatin capsules may be prepared with capsules containing the active compound of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules. Hard gelatin capsules may contain granules of the crystal forms of the invention. Hard gelatin capsules may also contain the crystal forms in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.

Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the crystal forms of the invention mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule which contains the crystal forms of the invention in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent or solution just prior to administration.

Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.1 % to 20 % by weight of the active ingredient and the remainder consisting of e.g. sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent or solution prior to use.

Solutions for parenteral administration may be prepared as a solution of a crystal form of the invention in a pharmaceutically acceptable solvent or solution, preferably in a concentration from 0.1 % to 10 % by weight. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent or solution extemporaneously before use.

The crystal forms according to the invention can also be used in formulations together with other active ingredients, e.g. for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa. Such other active ingredients may be antimicrobial agents, in particular:

- β -lactam antibiotics such as amoxicillin, ampicillin, cephalothin, cefaclor or cefixime;
- macrolides such as erythromycin, or clarithromycin;
- tetracyclines such as tetracycline or doxycycline;
- aminoglycosides such as gentamycin, kanamycin or amikacin;
- quinolones such as norfloxacin, ciprofloxacin or enoxacin;
- others such as metronidazole, nitrofurantoin or chloramphenicol; or
- preparations containing bismuth salts such as bismuth subcitrate, bismuth subsalicylate, bismuth subcarbonate, bismuth subnitrate or bismuth subgallate.

The crystal forms according to the invention can also be used in formulations together with other active ingredients, e.g. for the treatment or prophylaxis of conditions involving

medicament induced gastric ulcer. Such other active ingredients may be an NSAID, an NO-releasing NSAID, a COX-2 inhibitor or a bisphosphonate.

According to a further aspect of the invention there is provided a method of treatment of a condition where 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt according to the invention is required or desired, which method includes administering a therapeutically effective amount of a crystal form of the invention to a patient in need of such treatment.

For the avoidance of doubt, "treatment" includes the therapeutic treatment, as well as the prophylaxis, of a condition.

The crystal forms of the invention have the advantage that they are in a form that provides for improved ease of handling. Further, the crystal forms of the invention have the advantage that they may be produced in forms that have good chemical and solid state stability as well as low hygroscopicity. Thus, the crystal forms may be stable when stored over prolonged periods. The crystals forms of the invention are easily isolated crystals which also are stable at low temperature.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A can be prepared by adding, at a higher temperature, methane sulfonic acid to a mixture of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide, prepared according to WO 99/55706, in a lower alcohol, or preferably in an aqueous or methanolic mixture thereof.

The crystal form A of the invention precipitates and the crystals are isolated.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B is prepared by adding methane sulfonic acid to a mixture of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide, prepared according to WO 99/55706, in a lower alcohol, or in an aqueous or methanolic mixture thereof. The crystal form B of the invention is obtained

if the reaction is performed at a lower temperature. Form B of the crystal forms of the invention precipitates and the crystals are isolated.

Form A can also be obtained by suspending or recrystallisation of form B of the crystal forms of the invention in a single solvent or in a mixture of solvents, selected from water and lower alcohols, or preferably in an aqueous or methanolic mixture thereof. The suspending, or dissolving, is preferably performed at a higher temperature. The crystallisation may be initiated by seeding with form A of the crystal forms of the invention.

Form B can also be obtained by suspending or recrystallisation of form A. This is performed by suspending, or dissolving, form A of the crystal forms of the invention in a single solvent or in a mixture of solvents, selected from lower alcohols. The suspending and recrystallization is performed at a lower temperature. The crystallisation may be initiated by seeding with form B of the crystal forms of the invention.

Another aspect of the invention is mixtures of different crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt having advantageous properties.

The different crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt, i.e. form A and B are anhydrides of the compound of the invention.

The invention is illustrated, but in no way limited, by the following examples.

Examples

General Procedures

X-ray powder diffraction (XRPD) analysis was performed on samples prepared according to standard methods, for example those described in Giacovazzo, C. et al (1995),

Fundamentals of Crystallography, Oxford University Press; Jenkins, R. and Snyder, R. L. (1996), Introduction to X-Ray Powder Diffractometry, John Wiley & Sons, New York; Bunn, C. W. (1948), Chemical Crystallography, Clarendon Press, London; or Klug, H. P. & Alexander, L. E. (1974), X-ray Diffraction Procedures, John Wiley and Sons, New York. X-ray analyses were performed using a Siemens D5000 diffractometer and/or a Philips X'Pert MPD.

Differential scanning calorimetry (DSC) was performed using a Perkin Elmer DSC 7 instrument, according to standard methods, for example those described in Höhne, G. W. H. et al (1996), *Differential Scanning Calorimetry*, Springer, Berlin.

Thermogravimetric analysis (TGA) was performed using a Perkin Elmer TGA 7 instrument.

DSC onset temperatures may vary in the range $\pm 5^\circ\text{C}$ (e.g. $\pm 2^\circ\text{C}$), and XRPD distances may vary in the range ± 2 on the last decimal place.

Single crystal X-ray diffraction data were collected at room temperature with an Enraf-Nonius Kappa-CCD instrument equipped with graphite mono-chromatized MoK(α) radiation (2000). Accurate unit cell parameters were obtained from a real-space vector search that indexed all observed diffraction spots.

EXAMPLES

1. Preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A.

Example 1:1

100 g of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide was suspended in 200 ml ethanol. The suspension was heated to approximately 60°C and a mixture of methanesulphonic acid (28.9 g) and ethanol (40 ml)

was charged during approximately 80 minutes. After rinsing with ethanol (10 ml), suspension was cooled to approximately 50 °C. The crystals were isolated and washed with ethanol. The crystals were dried (dry-blowing) during 1.5 h. 102 g of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A was obtained.

Example 1:2

3.0 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was suspended in 6 ml water. The suspension was seeded with crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A (0.02 g). The suspension was stirred for approximately 2 hours at 40 °C. A sample was filtered off and analyzed. The sample was verified (XRPD) to consist of crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A.

Example 1:3

150 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was suspended in 11.25 ml water and 101 ml ethanol. The suspension was stirred at about 40 °C for 5 h. A sample was filtered off and analyzed. The sample was verified (XRPD) to consist of crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A.

The crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A, according to the present invention, are characterized in providing an X-ray powder diffraction pattern, as in figure 1, exhibiting substantially the following d-values and intensities;

Form A		Form A		Form A	
d-value (Å)	Relative intensity	d-value (Å)	Relative intensity	d-value (Å)	Relative intensity
11.4	vs	5.7	s	3.96	m
9.3	s	5.0	w	3.92	s
8.0	m	4.72	s	3.86	m
7.8	s	4.66	m	3.68	w
7.4	vw	4.62	w	3.63	w
7.3	w	4.49	w	3.56	m
6.8	w	4.43	m	3.42	w
6.5	vw	4.35	m	3.18	m
6.1	m	4.29	w		
5.8	m	4.10	w		

The peaks, identified with d-values calculated from the Bragg formula and intensities, have been extracted from the diffractogram of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A. The relative intensities are less reliable and have been estimated without any divergence slit conversion.

Definition relative intensities:

vs very strong
s strong
m medium
w weak
vw very weak.

It will be understood that the relative intensities of peaks may vary according to the orientation of the sample under test and on the type and setting of the instrument used so that the intensities in the X-ray powder diffraction traces included herein are illustrative and not intended to be used for absolute comparison.

Differential scanning calorimetry (DSC) on form A showed an endotherm melting with an onset of ca 255 °C.

TGA showed a decrease in mass of ca 0.5 % (20-100 °C).

Single crystals X ray diffraction analysis showed that form A crystallises as monoclinic in the space group $P2_1/c$ with four molecules in the unit cell. The unit cell dimensions were found to be:

$$a = 8.575(1) \text{ \AA}$$

$$b = 18.653(1) \text{ \AA}$$

$$c = 15.794(1) \text{ \AA}$$

$$\alpha = 90^\circ$$

$$\beta = 113.21(1)^\circ$$

$$\gamma = 90^\circ$$

$$V = 2371.0(4) \text{ \AA}^3$$

The calculated density is $D_c = 1.296(1) \text{ g/cm}^3$.

2. Preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.

Example 2:1

110 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide was suspended in 550 ml ethanol. 32 g methanesulphonic acid, diluted with 80 ml ethanol was charged. After rinsing with ethanol (30 ml), the suspension was stirred at room temperature until conversion to 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was complete. The suspension was cooled to 2 °C at -10 °C/h. The crystals were isolated and vacuum dried over the night at 30 °C. 133 g of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was obtained.

Example 2:2

75 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide was suspended in 350 ml ethanol and cooled to 10 °C. 21.9 g methanesulfonic acid, diluted with 56 ml ethanol was charged. After rinsing with ethanol (44 ml), the suspension was stirred until conversion to 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide mesylate salt form B was complete. The crystals were isolated and vacuum dried at 30 °C over night. 93 g of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide mesylate salt form B was obtained. Yield 99 %.

Example 2:3

20 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide was suspended in 99.2 ml ethanol mixed with 0.8 ml water. 3.94 ml methanesulfonic acid, diluted with 15 ml ethanol was charged at 7 °C. The suspension was stirred and sampled after 5 hours. The sample was verified to consist of crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide mesylate salt form B.

Example 2:4

20 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide was suspended in 98.1 ml ethanol mixed with 1.9 ml water. 3.94 ml methanesulfonic acid, diluted with 15 ml ethanol, was charged at 2 °C. During the charging procedure, the suspension was seeded with crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B. The suspension was stirred and sampled after 6 hours. The sample was verified (XRPD) to consist of crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide mesylate salt form B.

Example 2:5

10 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazol[1,2-a]pyridine-6-carboxamide was suspended in 47 ml *iso*-propanol. 1.97 ml methanesulfonic acid,

diluted with 11 ml *iso*-propanol, was added at 10 °C. The slurry stirred over night and then sampled. The sample was verified (XRPD) to consist of crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.

5 *Example 2:6*

2.0 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A was suspended in 3 ml ethanol.

The suspension was seeded with a "small amount" of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B. The suspension was stirred over night at room temperature. The crystals were isolated. A sample was filtered off and analyzed. The sample was verified (XRPD) to consist of crystals of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.

15 *Example 2:7*

2.0 g of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A was suspended in 3 ml of ethanol/methanol (1:1). To the suspension, 10 mg of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was added. Stirring was continued for 17 h in room temperature. The solid, 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B, was filtered off. Yield 87 %.

25 *Example 2:8*

2.0 g 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A was suspended in 3 ml ethanol/*iso*-propanol (1:1). To the suspension, 10 mg of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was added as seeds. The slurry was stirred in 16 h at room temperature. The solid 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B was filtered off. Yield 93%.

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B, according to the present invention, is characterized in providing an X-ray powder diffraction pattern, as in figure 2, exhibiting substantially the following d-values and intensities;

Form B		Form B		Form B	
d-value (Å)	Relative intensity	d-value (Å)	Relative intensity	d-value (Å)	Relative intensity
19.5	w	6.8	w	4.72	m
11.8	s	6.5	w	4.52	m
11.1	m	6.4	w	4.35	w
9.8	vs	5.9	m	3.89	w
8.3	s	5.5	m	3.68	w
7.8	w	4.96	w	3.26	m

The peaks, identified with d-values calculated from the Bragg formula and intensities, have been extracted from the diffractogram of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B. The relative intensities are less reliable and have been estimated without any divergence slit conversion.

Differential scanning calorimetry (DSC) on form B showed an exothermal event with an onset of 112 °C and an endotherm melting with an onset of 255 °C.

TGA showed a decrease in mass of *ca* 0.2 % (21-100 °C).

Single crystals X ray diffraction analysis showed that form B crystallises as triclinic in the space group $P(-1)$ (space group No. 2) with four molecules in the unit cell. The unit cell dimensions were found to be:

$$a = 8.440(1)$$

$$5 \quad b = 14.244(1)$$

$$c = 19.898(1) \text{ \AA}$$

$$\alpha = 93.03(1)^\circ$$

$$\beta = 99.88(1)^\circ$$

$$\gamma = 96.81(1)^\circ$$

$$10 \quad V = 2333.5(4) \text{ \AA}^3.$$

The calculated density is $D_c = 1.317(1) \text{ g/cm}^3$.

PRU03-19-18

CLAIMS

1. 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A, characterized in providing an X-ray powder diffraction pattern exhibiting substantially the following d-values:

Form A		
d-value (Å)	d-value (Å)	d-value (Å)
11.4	5.7	3.96
9.3	5.0	3.92
8.0	4.72	3.86
7.8	4.66	3.68
7.4	4.62	3.63
7.3	4.49	3.56
6.8	4.43	3.42
6.5	4.35	3.18
6.1	4.29	
5.8	4.10	

2. 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B, characterized in providing an X-ray powder diffraction pattern exhibiting substantially the following d-values:

Form B		
d-value (Å)	d-value (Å)	d-value (Å)
19.5	6.8	4.72
11.8	6.5	4.52
11.1	6.4	4.35

9.8	5.9	3.89
8.3	5.5	3.68
7.8	4.96	3.26

3. 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt, characterized in being a mixture of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A and 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.
4. A process for the preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A as defined in claim 1 comprising the steps of:
- a) dissolving or suspending 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide in a suitable solvent;
 - b) adding methanesulfonic acid at a higher temperature;
 - c) allowing the solution or suspension to crystallize; and
 - d) isolating the 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A thus obtained.
5. A process for the preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B as defined in claim 2 comprising the steps of:
- a) dissolving or suspending 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide in a suitable solvent;
 - b) adding methanesulfonic acid at a lower temperature;
 - c) allowing the solution or suspension to crystallize; and
 - d) isolating the 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B thus obtained.

6. A process for the preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A as defined in claim 1 comprising the steps of:
- a) dissolving or suspending any form of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt in a suitable solvent;
 - b) allowing the solution or suspension to crystallize at higher temperature, optionally using 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A to induce crystallization; and
 - c) isolating the 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A thus obtained.
7. A process for the preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B as defined in claim 2 comprising the steps of:
- a) dissolving or suspending any form of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt in a suitable solvent;
 - b) allowing the solution or suspension to crystallize at a lower temperature, optionally using 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B to induce crystallization; and
 - c) isolating the 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B thus obtained
8. A process for the preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A according to claim 6 wherein the form of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt is 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B.

9. A process for the preparation of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B according to claim 7 wherein the form of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt is 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A.
10. A process according to any of claims 4 or 5, characterized in that seeds are added to the solution or suspension to induce crystallization.
11. 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A or form B prepared according to any of claims 4 to 10.
12. A pharmaceutical formulation comprising 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt as defined in any one of claims 1 to 3 in admixture with at least one pharmaceutically acceptable excipient.
13. A pharmaceutical formulation in accordance with claim 12 comprising a mixture of the crystallines form of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt as defined in claims 1 to 3.
14. The use of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt as defined in any one of claims 1 to 3 in therapy.
15. The use of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt as defined in any one of claims 1 to 3 as active ingredient in the manufacture of a medicament for use in treatment of gastrointestinal disorders.

16. A method of treatment of gastrointestinal disorders which comprises administration of a therapeutically effective amount of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt as defined in any of claims 1 to 3, to a patient suffering therefrom.

2000000

ABSTRACT

The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to use of said compounds for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them and processes for obtaining them.

1/2




Figure 1.

An X-ray powder diffractogram of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form A measured with variable slits.



An X-ray powder diffractogram of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt form B measured with variable slits.

[illegible]